TITLE

Production technologies change flu vaccine landscape

AUTHOR(S)
Sheridan, Cormac
PUB. DATE
July 2007
SOURCE
Nature Biotechnology;Jul2007, Vol. 25 Issue 7, p701
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the continuous expansion of franchises for the production of influenza vaccines. It is noted that vaccine manufacturers have to order bred hens' eggs up to 12 months in advance of production. The author mentioned that firm Protein Sciences Corp. has realized that the influenza vaccine market is tough and need to target its high-dose vaccine at the elderly and at those unable to take existing vaccines because of egg allergy.
ACCESSION #
25681906

 

Related Articles

  • Delays expected for 2000-01 influenza vaccine shipments.  // Hudson Valley Business Journal;09/25/2000-10/09/2000, Vol. 11 Issue 16, p28 

    Reports on the expected delays of influenza vaccine shipments in the United States for the 2000-2001 season. Recommendation that mass influenza vaccine campaigns for the 2000-2001 season be delayed until early to mid-November; Factors responsible for causing the potential delay and possible...

  • 'Quicker' flu vaccine under development.  // GP: General Practitioner;2/24/2006, p6 

    The article discusses the development of a vaccine for the treatment of flu disease in the United States. A new production method which would allow a large quantity of flu vaccine would be produced in weeks instead of months. Although the U.S. states governments have placed advance orders for a...

  • Pandemic threat reignite's influenza vaccine market.  // PharmaWatch: Biotechnology;Jun2006, Vol. 5 Issue 6, p29 

    The article focuses on the role of impending pandemic to the renewed interest in the influenza vaccine market in the U.S. Double-digit growth rates have expanded the global flu vaccine market to an estimated $1.6 billion in 2005. Datamonitor forecasted that the influenza vaccine market in the...

  • Antidote. Siegel, Marc // Medical Marketing & Media;Nov2005, Vol. 40 Issue 11, p12 

    Comments on the concern about the flu vaccine shortage in the U.S. Issue involving the length of time to develop an effective vaccine; Inclusion of generic products in vaccine; Contribution to the slowing profit margin of the vaccine industry.

  • WHO: Production of Flu-Vaccine to Double by 2015. Greb, Erik // BioPharm International;Sep2011, Vol. 24 Issue 9, p18 

    The article reports on the views of World Health Organization (WHO) executive Marie Paule Kieny on global seasonal influenza vaccine production who believes that it will double to 1.7 billion doses by 2015.

  • Chapter 6: IMMUNIZATION: 6A: Vaccines.  // Monthly Prescribing Reference;Aug2014, Vol. 30 Issue 8, p137 

    The article offers brief information on several vaccines including the Adacel from the firm Sanofi Pasteur, the Cervarix from the firm GlaxoSmithKline, and the Flublok from the firm Protein Sciences.

  • Flu vaccine delay.  // Wellness Options;2006, Issue 27, p17 

    The author reports that the flu vaccine for the flu season of 2006-2007 will not be available until the end of October or early November in Canada. Vaccine manufacturers had difficulties growing one of the flu strains. Vaccines should be available before the peak season, which usually occurs...

  • Lawsuit puts flu-vaccine contract in doubt. Ledford, Heidi // Nature;7/2/2009, Vol. 460 Issue 7251, p21 

    The article reports on the lawsuit filed by Emergent BioSolutions Inc. against Protein Sciences Corp. for failing to pay the loan of more than $11 million it borrowed from Emergent in 2009 in the U.S. It states that Biomedical Advanced Research and Development Authority (BARDA), which awarded...

  • Panel: FluBlok Safety, Efficacy Data Insufficient for All Adults. Young, Donna // BioWorld Today;11/20/2009, Vol. 20 Issue 225, p1 

    The article reports an obstacle to the goal of Protein Science Inc. to become the first company in the U.S. to gain approval of a cell-based flu vaccine. A Food and Drug Administration (FDA) panel claims that FluBok's safety data were insufficient as the efficacy data would only support approval...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics